- Home
- CAI vs TPG Comparison
CAI vs TPG Comparison
Compare CAI & TPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAI
- TPG
- Stock Information
- Founded
- CAI 2008
- TPG 1992
- Country
- CAI United States
- TPG United States
- Employees
- CAI N/A
- TPG N/A
- Industry
- CAI Medical Specialities
- TPG Investment Managers
- Sector
- CAI Health Care
- TPG Finance
- Exchange
- CAI Nasdaq
- TPG Nasdaq
- Market Cap
- CAI 8.6B
- TPG 8.6B
- IPO Year
- CAI 2025
- TPG 2022
- Fundamental
- Price
- CAI $29.66
- TPG $56.40
- Analyst Decision
- CAI Strong Buy
- TPG Buy
- Analyst Count
- CAI 6
- TPG 14
- Target Price
- CAI $35.50
- TPG $65.69
- AVG Volume (30 Days)
- CAI 823.8K
- TPG 1.6M
- Earning Date
- CAI 11-12-2025
- TPG 11-04-2025
- Dividend Yield
- CAI N/A
- TPG 3.17%
- EPS Growth
- CAI N/A
- TPG N/A
- EPS
- CAI N/A
- TPG N/A
- Revenue
- CAI $533,847,000.00
- TPG $3,887,230,000.00
- Revenue This Year
- CAI $64.66
- TPG N/A
- Revenue Next Year
- CAI $45.81
- TPG $25.02
- P/E Ratio
- CAI N/A
- TPG $1,057.06
- Revenue Growth
- CAI 106.53
- TPG 43.35
- 52 Week Low
- CAI $25.40
- TPG $37.52
- 52 Week High
- CAI $42.50
- TPG $72.98
- Technical
- Relative Strength Index (RSI)
- CAI N/A
- TPG 41.15
- Support Level
- CAI N/A
- TPG $55.04
- Resistance Level
- CAI N/A
- TPG $59.30
- Average True Range (ATR)
- CAI 0.00
- TPG 1.96
- MACD
- CAI 0.00
- TPG -0.35
- Stochastic Oscillator
- CAI 0.00
- TPG 29.84
About CAI Caris Life Sciences Inc. Common Stock
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
About TPG TPG Inc.
TPG Inc is an alternative asset management firm. It invests across five multi-product platforms namely Capital, Growth, Impact, Real Estate, Market Solutions, and TPG Angelo Gordon. The company focuses on large-scale, control-oriented private equity investments.